KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Rigel Pharmaceuticals (RIGL) over the last 17 years, with Q3 2025 value amounting to $3.4 million.

  • Rigel Pharmaceuticals' Share-based Compensation rose 2719.36% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.0 million, marking a year-over-year decrease of 154.42%. This contributed to the annual value of $12.4 million for FY2024, which is 4073.36% up from last year.
  • Rigel Pharmaceuticals' Share-based Compensation amounted to $3.4 million in Q3 2025, which was up 2719.36% from $3.3 million recorded in Q2 2025.
  • Rigel Pharmaceuticals' Share-based Compensation's 5-year high stood at $5.1 million during Q1 2024, with a 5-year trough of $1.9 million in Q4 2023.
  • Moreover, its 5-year median value for Share-based Compensation was $2.6 million (2021), whereas its average is $2.8 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first plummeted by 5262.25% in 2023, then soared by 8614.94% in 2024.
  • Rigel Pharmaceuticals' Share-based Compensation (Quarter) stood at $2.3 million in 2021, then skyrocketed by 74.43% to $4.1 million in 2022, then plummeted by 52.62% to $1.9 million in 2023, then increased by 7.97% to $2.1 million in 2024, then soared by 61.14% to $3.4 million in 2025.
  • Its Share-based Compensation stands at $3.4 million for Q3 2025, versus $3.3 million for Q2 2025 and $3.3 million for Q1 2025.